Previous close | 29.76 |
Open | 29.43 |
Bid | 29.01 x 200 |
Ask | 29.17 x 100 |
Day's range | 28.99 - 29.45 |
52-week range | 18.61 - 39.26 |
Volume | |
Avg. volume | 361,755 |
Market cap | 1.65B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 12.52 |
EPS (TTM) | 2.32 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 43.00 |
Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL on Monday, June 10, 2024, at 9:20 a.m. ET.
Investors in Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) had a good week, as its shares rose 7.7% to close at...